# Luo Fayong

> Luo Fayong is a Series C investor at EFung Capital backing Medical and Health Care. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [EFung Capital](https://shizune.co/investors/profile/efung-capital)
- Total investments: 1
- Last investment: Oct 2019
- Lead investor: 0%
- Last updated: Aug 2026

Luo Fayong is a Series C investor at EFung Capital focused on Medical and Health Care. He is the Managing Director at EFung Capital.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 100% |
| Health Care | 1 | 100% |
| Clinical Trials | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| WeMed | Developer of digital angiography machines intended to be used in the clinical fields of radiology and cardiology. |  | Series C | Oct 21, 2019 |  |

1 of 1 investments shown.

## Co-investors
- [Dongpingheng Investment](https://shizune.co/investors/profile/dongpingheng-investment-5ed7) — VC Fund, 1 deal together
- [Dynamic Balance Capital](https://shizune.co/investors/profile/dynamic-balance-capital) — VC Fund, 1 deal together
- [Lucion](https://shizune.co/investors/profile/lucion) — VC Fund, 1 deal together

## About EFung Capital

VC Fund · Shenzhen, China

Shenzhen EFUNG Investment Management Enterprise L. P. is one of China's earliest institutions investing in professional biomedical industries. Their strong research team and great investment returns made us won 'The Most Pioneering VC Institution” 'The Most Dynamic Pharmaceutical VC Institution in China' and 'The Top Ten VCInstitutions in Shenzhen'. With this influence, EFUNG has drawn a lot of attention from the medical and life science industry. And it is interviewed by Nature, which is the most authoritative science magazine in the world. Over a decade of years, they have been focusing on the medical and health industry, especially the VC and PE investment business of novel drugs and high-end medical devices. The mission of EFUNG is to drive the industrialization of medical researches by capital and to gain rich returns to investors. EFUNG has deeply screened and invested in more than 20 domestic and international premium enterprises, such as Chipscreen Biosciences, Frontier Biotechnologies, Ascentage Pharma, Lifotronic, Aridis Pharmaceuticals, and Centrexion.

4 contacts available at EFung Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Jinqiao Zhu | Founder | https://shizune.co/investors/profile/jinqiao-zhu |
| Luo Fayong | Managing Director | https://shizune.co/investors/profile/luo-fayong |
| Pai Zhu | Managing Partner | https://shizune.co/investors/profile/pai-zhu |
| Yu Wang | Chief Scientist | https://shizune.co/investors/profile/yu-wang-87d2 |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Luo Fayong invest in?

Luo Fayong invests primarily in Medical, Health Care and Clinical Trials startups, most often at Series C stage. Most of the 1 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Luo Fayong last invest?

The most recent investment recorded for Luo Fayong closed in Oct 2019. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co